Shares of Baxter International Inc. (NYSE:BAX – Get Free Report) have earned a consensus rating of “Hold” from the eleven analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $40.45.
Several research firms have recently weighed in on BAX. Stifel Nicolaus lowered their target price on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Citigroup decreased their price objective on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. Finally, StockNews.com cut shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Monday, November 11th.
Read Our Latest Research Report on BAX
Institutional Investors Weigh In On Baxter International
Baxter International Stock Up 0.1 %
Shares of BAX opened at $30.99 on Monday. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. The company has a 50-day moving average price of $31.14 and a two-hundred day moving average price of $34.70. The stock has a market cap of $15.82 billion, a price-to-earnings ratio of 154.94, a P/E/G ratio of 9.38 and a beta of 0.59. Baxter International has a 12 month low of $28.33 and a 12 month high of $44.01.
Baxter International (NYSE:BAX – Get Free Report) last posted its earnings results on Friday, November 8th. The medical instruments supplier reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Baxter International had a return on equity of 18.30% and a net margin of 0.77%. The business had revenue of $3.85 billion during the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter last year, the company earned $0.68 EPS. Baxter International’s revenue was up 3.8% on a year-over-year basis. Equities analysts predict that Baxter International will post 1.92 EPS for the current fiscal year.
Baxter International Cuts Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Friday, November 29th were issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 2.19%. The ex-dividend date of this dividend was Friday, November 29th. Baxter International’s dividend payout ratio is 340.02%.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Featured Articles
- Five stocks we like better than Baxter International
- Stock Dividend Cuts Happen Are You Ready?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.